Related Experiment Video
Updated: May 5, 2026

07:30
Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
Published on: May 10, 2018
8.3K
Augmentation of insulin secretion by a non-nutrient drink
Gastroenterology
|June 1, 1980
Summary
A hypertonic mannitol-electrolyte drink significantly augmented insulin release following intravenous glucose in normal subjects. This non-nutrient beverage enhanced glucose-stimulated insulin secretion, suggesting osmotic effects play a role.
Area of Science:
- Endocrinology
- Metabolic Research
- Gastroenterology
Background:
- Nutrients are known to stimulate insulin release.
- The role of non-nutrient stimuli, particularly osmotic load, on insulin secretion requires further investigation.
Purpose of the Study:
- To investigate the effect of a nutrient-devoid hypertonic drink on insulin release.
- To determine if osmotic load influences the insulin secretory response to intravenous glucose.
Main Methods:
- 13 healthy subjects received intravenous glucose infusion.
- The effect of pre-ingesting a 3% mannitol-electrolyte solution (osmolality ≥ 456 mosmol/kg) on insulin response was compared to a control.
- Responses to arginine infusion were also assessed following drink ingestion.
Main Results:
- Ingestion of the hypertonic mannitol-electrolyte drink increased insulin release by 56% during intravenous glucose infusion (P < 0.005).
- Post-infusion serum glucose levels were lower when the drink preceded glucose.
- The drink did not alter basal insulin or other measured hormones, and a less hypertonic solution (2%) lacked this effect. Arginine-stimulated insulin release was not enhanced.
Conclusions:
- A non-nutrient drink with high osmolality augments insulin secretion in response to intravenous glucose.
- Osmotic stimulation appears to be a key factor in enhancing glucose-induced insulin release.
- This finding has implications for understanding nutrient-independent regulation of insulin secretion.
Related Concept Videos
Insulin Secretory Vesicles
6.3K
Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
6.3K
Hormones Regulating Blood Glucose
7.6K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
7.6K
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
2.8K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
2.8K
Insulin: Dosing Regimen and Adverse Effects
1.3K
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.3K
Glucagon-like Receptor Agonists
1.3K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
Dipeptidyl Peptidase 4 Inhibitors
1.1K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K

